Clinical Trial: NCT04179929
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
Status:
RECRUITINGPhase:
Not Applicable| Lead Sponsor: | PETHEMA Foundation |
| Information Provided By: | PETHEMA Foundation |
| Last Update Posted: | 2022-02-18 |
Study Overview
Brief Summary
After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.
Official Title
Treatment of BCR-ABL Negative ALL in Adults According to MRD and Genetics
Conditions
Acute Lymphoblastic Leukemia
Intervention / Treatment
- Drug: Pediatric-type of chemotherapy
- Procedure: allogeneic HSCT
Other Study ID Numbers
- PETHEMA LAL-2019
Start Date (Actual)
2019-11-25
Primary Completion Date (Estimated)
2026-11
Study Completion Date (Estimated)
2027-02
Enrollment (Estimated)
300
Study Type
Interventional
Phase
Not Applicable
| Lead Sponsor: | PETHEMA Foundation |
| Information Provided By: | PETHEMA Foundation |
| Last Update Posted: | 2022-02-18 |
Study Overview
Brief Summary
After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.
Official Title
Treatment of BCR-ABL Negative ALL in Adults According to MRD and Genetics
Conditions
Acute Lymphoblastic Leukemia
Intervention / Treatment
- Drug: Pediatric-type of chemotherapy
- Procedure: allogeneic HSCT
Other Study ID Numbers
- PETHEMA LAL-2019
Start Date (Actual)
2019-11-25
Primary Completion Date (Estimated)
2026-11
Study Completion Date (Estimated)
2027-02
Enrollment (Estimated)
300
Study Type
Interventional
Phase
Not Applicable